Clinical trials data
Verbal Learning in multiple sclerosis trials: 139 registered studies
Every registered multiple sclerosis study on ClinicalTrials.gov that names Verbal Learning in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered multiple sclerosis studies name it in an outcome measure
- 139
- Name it in a primary outcome, 30%
- 42 of 139
Tests named in the same studies
- 1
Symbol Coding107 studies, 36 as a primary outcome
- 2
Paced Visual Serial Addition Test29 studies, 13 as a primary outcome
- 3
Verbal Fluency29 studies, 9 as a primary outcome
- 4
Stroop Color-Word Test19 studies, 7 as a primary outcome
- 5
Trail Making Test14 studies, 4 as a primary outcome
- 6
Digit Span Test9 studies, 1 as a primary outcome
- 7
Line Angle Matching6 studies, 2 as a primary outcome
- 8
Category Fluency4 studies, 2 as a primary outcome
- 9
Continuous Performance Test3 studies, 3 as a primary outcome
- 10
Selective Reminding Task3 studies, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 3 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 7 | 6 |
| 2014 | 5 | 3 |
| 2015 | 3 | 1 |
| 2016 | 7 | 1 |
| 2017 | 5 | 1 |
| 2018 | 6 | 2 |
| 2019 | 10 | 2 |
| 2020 | 6 | 0 |
| 2021 | 8 | 2 |
| 2022 | 16 | 4 |
| 2023 | 16 | 4 |
| 2024 | 18 | 5 |
| 2025 | 13 | 5 |
| 2026 | 12 | 3 |
Phases and study sizes
By phase
- Early phase 12 studies, 0 as a primary outcome
- Phase 12 studies, 0 as a primary outcome
- Phase 1/22 studies, 1 as a primary outcome
- Phase 28 studies, 2 as a primary outcome
- Phase 2/34 studies, 2 as a primary outcome
- Phase 311 studies, 1 as a primary outcome
- Phase 43 studies, 2 as a primary outcome
- Not applicable88 studies, 28 as a primary outcome
- Observational19 studies, 6 as a primary outcome
Participants per study
- Phase 3767 median, 157 to 969
- Not applicable50 median, 30 to 100
- Observational60 median, 60 to 120
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 3 | 11 | 767 | 157 to 969 |
| Not applicable | 88 | 50 | 30 to 100 |
| Observational | 19 | 60 | 60 to 120 |
When multiple sclerosis trials measure it
Latest time point of each outcome
- Within a day18 outcomes, 3 as a primary outcome
- Up to 4 weeks11 outcomes, 3 as a primary outcome
- 1 to 3 months46 outcomes, 16 as a primary outcome
- 3 to 6 months20 outcomes, 5 as a primary outcome
- 6 to 12 months15 outcomes, 7 as a primary outcome
- 1 to 2 years13 outcomes, 5 as a primary outcome
- Over 2 years10 outcomes, 0 as a primary outcome
- No duration given6 outcomes, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
133 of the 139 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting34 studies, 12 as a primary outcome
- Not yet recruiting8 studies, 2 as a primary outcome
- Active, not recruiting7 studies, 1 as a primary outcome
- Completed63 studies, 20 as a primary outcome
- Stopped early8 studies, 3 as a primary outcome
- Status unknown19 studies, 4 as a primary outcome
What they test
- Behavioral53 studies, 15 as a primary outcome
- Drug27 studies, 7 as a primary outcome
- Device19 studies, 5 as a primary outcome
- Dietary supplement6 studies, 4 as a primary outcome
- Procedure2 studies, 0 as a primary outcome
- Diagnostic test5 studies, 2 as a primary outcome
- Biological1 studies, 0 as a primary outcome
- Other28 studies, 8 as a primary outcome
- None given5 studies, 4 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States54 studies, 22 as a primary outcome
- Türkiye25 studies, 7 as a primary outcome
- Canada15 studies, 0 as a primary outcome
- Italy12 studies, 2 as a primary outcome
- Denmark11 studies, 0 as a primary outcome
- France10 studies, 1 as a primary outcome
- Netherlands10 studies, 0 as a primary outcome
- United Kingdom9 studies, 0 as a primary outcome
- Sweden8 studies, 1 as a primary outcome
- Portugal7 studies, 2 as a primary outcome
- Spain7 studies, 2 as a primary outcome
- Norway6 studies, 0 as a primary outcome
56 countries in all. A study with sites in several counts in each; 5 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed multiple sclerosis studies that name Verbal Learning: 24 of 63, 38%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed multiple sclerosis studies that name Verbal Learning | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 8, 13% | 776, 10% |
| Results on ClinicalTrials.gov only | 8, 13% | 1,139, 14% |
| A results paper only | 8, 13% | 1,711, 22% |
| Neither | 39, 62% | 4,327, 54% |
The 139 studies
139 studies match. 42 name Verbal Learning in a primary outcome. Median size 60 participants. Median time to the primary outcome: 13 weeks.
Loading 139 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 3 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 7 | 6 |
| 2014 | 5 | 3 |
| 2015 | 3 | 1 |
| 2016 | 7 | 1 |
| 2017 | 5 | 1 |
| 2018 | 6 | 2 |
| 2019 | 10 | 2 |
| 2020 | 6 | 0 |
| 2021 | 8 | 2 |
| 2022 | 16 | 4 |
| 2023 | 16 | 4 |
| 2024 | 18 | 5 |
| 2025 | 13 | 5 |
| 2026 | 12 | 3 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 14, other 125. Interventional 120, observational 19.
As a primary outcomeSecondary or other outcomeVerbal Learning
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07893925 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants38 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07880418 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants20 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07766213 | Start2026 | PhaseObservational | ConditionsMultiple sclerosis, Pain and fatigue | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07734675 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants130 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07710742 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis, Pain and fatigue | Participants51 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07680738 | Start2023 | PhaseNot applicable | ConditionsMultiple sclerosis, Pain and fatigue | Participants38 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07578740 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants40 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07571304 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants22 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07507084 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07504120 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis, Depression and bipolar disorder, Aging, frailty and exercise, Pain and fatigue | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07447115 | Start2027 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants30 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07434934 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants40 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07399262 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants32 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07355387 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants75 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07318129 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants220 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07230015 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07181811 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants30 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07160218 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants45 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07114809 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06992115 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06968039 | Start2024 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants85 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06966128 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06951919 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants125 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06877273 | Start2025 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants24 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT06874764 | Start2026 | PhaseNot applicable | ConditionsMultiple sclerosis | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many multiple sclerosis trials use Verbal Learning?
139 registered multiple sclerosis studies on ClinicalTrials.gov name it in an outcome measure, 42 of them in a primary outcome: 23% of the condition's 612 studies with a cognitive outcome, against 11% of all of them. It is the 3rd most named test in multiple sclerosis trials.
Which tests do multiple sclerosis trials use with Verbal Learning?
Symbol Coding (107 studies), the Paced Visual Serial Addition Test (29 studies) and Verbal Fluency (29 studies).
When do multiple sclerosis trials measure Verbal Learning?
Half of the primary outcomes that name Verbal Learning are measured within 13 weeks of the start, and the middle half from 8 weeks to 12 months. 39 primary outcomes give a duration.
How many completed multiple sclerosis trials that use Verbal Learning have reported results?
24 of the 63 completed studies that name it, 38%, have reported results: 16 posted them on ClinicalTrials.gov, 16 have a results paper linked to the registry record, and 8 did both. The other 39 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Verbal Learning and Grocery Trip Game as one test family, so this page counts their studies together.
Run Verbal Learning in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.